EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION

Michael Chiorean ¹
¹ Virginia Mason Medical Center

Topic
Histopathology, IBD

Session
IBD Clinical III

Conference
UEG Week Virtual 2020

Do you need help setting up your myUEG account?
Contact us at [email protected]

Social Sharing